Abstract: The invention relates to favourable combinations of the thiazide diuretic chlorthalidone with Angiotensin II Receptor Blockers (ARBs) for the treatment of hypertension.

Abstract: Pharmaceutical compositions for the treatment of nasal congestion or migraine, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective ?-2 adrenergic receptor agonists.

Abstract: Imido-acid salts and compositions containing imido-acid salts are described herein. Methods of their preparation and use are also described herein. The methods of using the imido-acid salts include the reduction of volatile compounds from gas and liquid streams and the delivery of pharmaceutical agents to subjects.

Abstract: Disclosed are compounds of Formula 1 and Formula 1A including all stereoisomers, N-oxides, and salts thereof, wherein Q1, Q2, R1, R2, R4, R5 and X are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 or Formula 1A and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Abstract: This invention is directed to pharmaceutical compositions for topical administration to a mammal, wherein the pharmaceutical compositions comprise a spiro-oxindole compound, as an enantiomer, a racemate or a non-racemic mixture, or a pharmaceutically acceptable salt thereof. These pharmaceutical compositions are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions.

Abstract: The invention relates to a method of controlling aphids that are resistant to neonicotinoid insecticides, using the compound spirotetramat in free form or in agrochemically acceptable salt form as well as the use of compositions comprising said compound to control neonicontinoid resistant insects. In particular the methods relate to controlling neonicotinoid resistant insects in the Aphididae family, that are resistant to one or more neonicotinoid insecticides. Methods of the invention find particular use in controlling neonicotinoid resistant insects in crops of useful plants. Furthermore, the invention extends to methods of controlling plant viruses spread by neonicotinoid resistant insects.

Abstract: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for diagnosis and treatment of diseases and conditions associated with expression of glucocorticoid receptor are provided.

Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.

Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.

Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG.

Abstract: This invention relates to a pharmaceutical composition for the treatment and/or prevention of at least one pathological neovascularization-related conditions of the interior of the eye, the composition comprising a therapeutically effective amount of an antisens oligonucleotide having the sequence SEQ ID NO: 1: 5?-TCTCCGGAGGGCTCGCCATGCTGCT-3? or any function conservative sequence comprising from 9 to 30 nucleotides that has 75%, 80%, 85%, 90%, 95% or more than 95%, 96%, 97%, 98%, 99% of identity compared to SEQ ID NO: 1 and that conserves the capacity of inhibiting IRS-1 gene expression as SEQ ID NO: 1, and the composition being administered within the posterior segment of the eye to a subject in need thereof; this invention also relates to a method for treating a pathological neovascularization-related condition of the interior of the eye in a subject in need thereof comprising administering to the subject a therapeutically effective amount of said pharmaceutical composition.

Abstract: The present invention relates to MST1 and MST2 cancer biomarkers. The inventors demonstrate herein that MST1 and/or MST2 can be used as biomarkers for the detection and prognosis of prostate cancer. The invention further discloses that enforced expression of MST1 can be used to inhibit and/or suppress the progression of prostate cancer.

Abstract: A polypeptide comprising a G-CSF domain operably linked to a Tf domain, wherein the ability of the polypeptide to be transported into a cell expressing a TfR gene or the ability of the polypeptide to be transported across a cell expressing a TfR gene via transcytosis is higher than that of the G-CSF domain alone.

Abstract: The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.

Abstract: Compositions and methods for treating neurological diseases and disorders are disclosed.

Abstract: Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.

Abstract: Methods, compositions and kits for regulating complement activity or treating a complement activity disorder in a subject using soluble, membrane-independent CD59 protein, methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein.

Abstract: The present invention relates to a cervical cancer therapeutic agent comprising a recombinant vector containing a gene that encodes adenylate cyclase activating polypeptide 1 (pituitary) (ADCYAP1). The use of the recombinant vector and a pharmaceutical composition comprising the recombinant vector can prevent or treat cervical cancer by inhibiting the proliferation of cervical cancer cells.

Abstract: Disclosed are compositions and methods involving cyclic di-GMP—responsive Riboswitches and cyclic di-GMP-II motifs.

Abstract: This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals.

Abstract: There is provided crystalline solvate forms of Warfarin potassium, termed APO-I and APO-II, and processes for making APO-I and APO-II. APO-I and APO-II are polymorphic solvate forms of Warfarin potassium.

Abstract: A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects.

Abstract: The invention relates to an extract and/or one or more natural compounds from plants or parts of plants, respectively, from a genus selected from Schisandra, Illicium, Kadsura, Steganotaenia or Magnolia, for the regulation of body weight, fat loss, and/or management of obesity, in humans or in animals, methods and uses of the same and to the use of the same or mixtures in the manufacture of a pharmaceutical or nutraceutical formulation. The above can further be used to reduce one or more adverse metabolic parameters in a subject. The invention relates also to said extract and/or compound(s) in the treatment or in the preparation of a medicament for treatment of obesity, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s), which are useful in the regulation of body weight and/or fat loss and/or for the management of obesity.

Abstract: Serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation.

Abstract: Carbamimidothioic acid esters of formula (I) and 2-nitro-N-[4-(pyridin-4-ylamino)phenyl]-4-(quinolin-4-ylamino)benzamide are used for the treatment of influenza, and for the inhibition of a viral RNA-dependent RNA polymerase. Formulae (I), (II).

Abstract: The present invention relates to adamantyl derivatives and their anti-cancer activity. Compounds of formulae I and II are provided as well as related methods of treatment and methods of synthesis.

Abstract: A stable galenic composition of a compound of general formula (I) wherein R1 and R2 both represent independently of each other an alkyl, aryl, arylalkyl group, optionally substituted with one or more linear or branched groups, optionally bearing one or more heteroatoms, comprising said compound of formula I in an amount ranging from 0.01 to 15% by weight based on the total weight of the final composition; at least one anhydrous ester, the main chain and/or optionally the branched chains of which are free from free and/or reactive groups or functions, in an amount ranging from 0.1 to 99.9% by weight based on the total weight of the cosmetically and pharmaceutically acceptable composition; and optionally a cosmetically and pharmaceutically acceptable excipient for completing the 100% of the total weight of the composition.

Abstract: Disclosed are a sympathetic inhibitor allowing more effective inhibition of activity of a sympathetic nerve, as well as a cosmetic composition, a food, and a sundry article containing the same. Ethyl 4-methoxybenzoate is efficacious for quieting down the activity of the sympathetic nerve. The sympathetic inhibitor, the cosmetic composition, the food and the sundry article containing the same enable more effective inhibition of the activity of the sympathetic nerve.

Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.

Abstract: The use of sterculic acid, and the pharmaceutically acceptable salt forms thereof, described for the treatment of inflammation, in particular, 7-ketocholesterol induced inflammation, 7-keto-cholesterol toxicity, and unregulated angiogenesis.

Abstract: S-allylmercapto-N-acetylcysteine and related compounds are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compounds include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia.

Abstract: The present invention is directed to methods and compositions for the treatment of diabetes and related symptoms. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diabetes and related symptoms. In a method aspect, the present invention provides a method of treating diabetes. The method involves ingesting 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diabetes.

Abstract: A composition and method of increasing the bioavailability of curcumin is provided. A synergistic combination of excipient polymers provides increased bioavailability thereby increasing the plasma concentration of curcumin and its metabolite curcumin O-glucuronide. The curcumin pharmaceutical compositions are suitable for modifying DNA methylation and treating diseases such as cancer.

Abstract: The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least tungsten and/or tantalum metal making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for treating herniated invertebral discs but also in intervention having demonstrated the efficacy of pure ethanol: treatment of hepatocellular tumours or osteoid osteomas, renal cysts and arterial-veinous angiomas.

Abstract: Hydrocarbon oil obtained by Fischer-Tropsch synthesis reaction using a slurry bed reactor holding a slurry of a liquid hydrocarbon in which a catalyst is suspended; the hydrocarbon oil is fractionated into a distilled oil and a column bottom oil containing the catalyst fine powder by a rectifying column; at least part of the column bottom oil is transferred to a storage tank, and the catalyst fine powder is sedimented to the bottom of the storage tank to capture the catalyst fine powder; a residue of the column bottom oil is transferred from the rectifying column to a hydrocracker, and/or the supernatant of the column bottom oil from which the catalyst fine powder is captured by the storage tank is transferred from the storage tank to the hydrocracker; and using the hydrocracker, the residue of the column bottom oil and/or the supernatant of the column bottom oil is hydrocracked.

Abstract: The invention relates to integrated processes for producing industrial chemicals, such as alcohols, carboxylic acids, esters, aldehydes, olefins and polymers from biomass. In one embodiment, the invention is to a process comprising the steps of (a) introducing biomass and an oxygen stream to a gasifier and converting the biomass into a product gas, wherein the gasifier is operated at a pressure of at least 10 bar; (b) compressing the product gas at a compression ratio that is less than 5:1 to form compressed product gas; (c) directing a first portion of the compressed product gas to an alcohol synthesis reactor to produce methanol; (d) directing a second portion of the compressed product gas to a gas separator to produce a hydrogen stream and a carbon monoxide stream; (e) reacting the carbon monoxide stream with the methanol to produce acetic acid; and (f) reacting the hydrogen stream with acetic acid to produce ethanol.

Abstract: The invention relates to integrated processes for producing industrial chemicals, such as alcohols, carboxylic acids, esters, aldehydes, olefins and polymers from biomass. In one embodiment, the invention is to a process comprising the steps of: introducing biomass and an oxygen stream to a gasifier and converting the biomass into a product gas, wherein the gasifier is operated at a pressure of at least 10 bar; compressing the product gas at a compression ratio that is less than 3:1 to form a compressed product gas; directing a first portion of the compressed product gas to an alcohol synthesis reactor to produce methanol; reacting carbon monoxide with the methanol to produce acetic acid; esterifying the acetic acid with ethanol to form ethyl acetate; and reducing the ethyl acetate with hydrogen in the presence of a catalyst to form ethanol.

Abstract: A method for preparing contaminated plastics ground into flakes, such as RPET or such polymers, having at least decontamination and SSP treatment steps, with at least one reactor, with heating to the process temperature taking place essentially outside the reactor. Also, a device for carrying out the method, and having at least one decontamination reactor and at least one SSP reactor, a device for heating plastic flakes to the process temperature being arranged upstream of the decontamination reactor. Also an SSP reactor having at least two individual reactors, and preferably between 3 and 7 individual reactors.

Abstract: The presently disclosed subject matter relates generally to method of producing thermoplastic foam from a blend of polyolefin and acrylated epoxidized fatty acid using a phsyical blowing agent. Specifically, the presently disclosed subject matter includes embodiments wherein the acrylated epoxidized fatty acid is added to the polyolefin resin in an amount of from about 0.1% to about 10%, based on the total weight of the resin. The presently disclosed subject matter also includes the foam produced by the disclosed method.

Abstract: A medical device includes a substrate having at least a portion thereof functionalized with at least one reactive member and a chemotactic agent functionalized with at least one complementary reactive member, wherein the at least one reactive member and the at least one complementary reactive member are covalently bonded, adhering the chemotactic agent to the substrate.

Abstract: Copolymers of propylene oxide and ethylene oxide have an inner block that contains from 65-90 weight percent oxyethylene units and from 10 to 35 weight percent oxypropylene units. This block has a molecular weight of from 150 to 350. The copolymer has an outer block which contains at least 95 weight % oxypropylene units and from 0 to 5% oxyethylene units. The equivalent weight of the copolymer is from 800 to 2000. The copolymers are useful in making polyurethane foams that have unexpectedly high tensile and/or tear strengths.

Abstract: Disclosed is a coating composition that when dried and cured, provides a coating composition having excellent scratch and mar resistance. The coating composition is cures upon exposure to ultraviolet radiation. The coating composition comprises a film forming binder that is a polymer having poly(trimethylene ether) repeat units and in the range of from 1 to 20 ethylenically unsaturated double bonds. The coating composition is especially useful as a clearcoat composition in the automotive industry.

Abstract: A composition for production of a crosslinkable pressure-sensitive adhesive for skin, obtained by dissolving in a solvent 100 parts by weight of an acrylic copolymer (copolymer A) comprising a (meth)acrylic acid alkyl ester as the main constituent component and 3-45 wt % diacetoneacrylamide as an essential constituent component, and containing no free carboxyl groups, and 0.1-30 parts by weight of an acrylic copolymer (copolymer B) comprising a (meth)acrylic acid alkyl ester as the main constituent component and a primary amino group and/or carboxyhydrazide group on a side chain, and containing no free carboxyl groups.

Abstract: The present invention is a drying composition comprising spherical beads and a stable aqueous dispersion of polymer particles and also a dried composition of the spherical beads and a polymer film. The composition is useful as a wall repair formulation.

Abstract: To provide a resin composition having excellent thermal conductivity and excellent insulation reliability, a molded object, a substrate material, and a circuit board. [Solution] Provided is a resin composition which comprises an epoxy resin, a hardener, and an inorganic filler, wherein the epoxy resin and/or the hardener has a naphthalene structure, the inorganic filler comprises hexagonal boron nitride, and the inorganic filler accounts for 50-85 vol. % of the whole resin composition. Since a naphthalene structure, which imparts the satisfactory ability to wet the hexagonal boron nitride included in the inorganic filler, has been introduced into the epoxy resin and/or the hardener to heighten the inorganic-filler loading characteristics, this resin composition attains excellent heat dissipation properties, heat resistance, insulating properties, etc.

Abstract: A coating composition comprising an advanced epoxy resin polymeric composition having the following chemical structure:(formula) I where n is a number from 1 to about 3000; each m independently has a value of 0 or 1; each R0 is independently —H or —CH3; each R1 is independently —H or a C1 to C6 alkylene radical (saturated divalent aliphatic hydrocarbon radical); R?1—R?4 are independently hydrogen, an alkyl, cycloalkyl, an aryl or an aralkyl group or other substituent, for example, a nitro, an isocyanate, or an alkyloxy group; additionally, any two of R?1-R?4 may form fused ring independently; and X is cycloalkylene group, including substituted cycloalkylene group, where the substituent groups include an alkyl, cycloalkyl, an aryl or an aralkyl group or other substituent group, for example, a halide, a cyano, a nitro, a blocked isocyanate, or an alkyloxy group; the combination of cycloalkylene and alkylene groups and the combination of alkylene and cycloalkylene group with a bridging moiety in between.

Abstract: According to the invention, a liquid resin composition which has favorable wet spreadability after mounting of a chip and exhibits excellent solder cracking resistance even in a high-temperature solder reflow process at about 260° C., i.e., even when being used in lead-free solder, and a semiconductor package using the liquid resin composition are provided. In the liquid resin composition of the invention, an acrylic copolymer having a radical polymerizable functional group contains alkyl(meth)acrylate as a constituent monomer having a linear or branched alkyl group having 6 to 9 carbon atoms in an amount of 10 wt % to 40 wt % of the entire constituent monomers.

Abstract: The invention relates to curable compositions which comprise epoxy resins, amino hardeners, and a phosphonate of the formula I. Addition of phosphonate of the formula I can give cured epoxy resins which have not only improved flame retardants but also an increased glass transition temperature when comparison is made with the corresponding resins without said addition.

Abstract: We disclose a method of making an asphalt composition containing large quantities of ground tire rubber. Over 20% GTR by weight can be used in the asphalt composition without the GTR settling out. The method comprises a series of heating and blending and using a GTR stabilizer.

Abstract: A film may be formed from film forming compositions which comprise at least one carboxamide based coalescing solvent. These coalescing solvents impart equivalent or improved wet-scrub resistance, block resistance, gloss, dirt pick-up resistance and leveling characteristics to the films on a substrate, without contributing to total VOC levels, when replacing conventional coalescing solvents. The present invention also includes a method for forming a film comprising applying a film forming composition comprising polyunsaturated reactive carboxamides to a substrate and curing the film under ambient conditions. The coalescing carboxamide solvents are suitable for paint, latex based caulk, adhesives and floor care applications.